ChemoCentryx Inc. is expanding its alliance with Vifor Pharma to develop and commercialize another of its kidney drugs.
The companies will jointly develop CCX140 for more prevalent forms of chronic kidney disease with ChemoCentryx retaining rights in U.S. and China, and Vifor Pharma for the rest of the world.
ChemoCentryx will receive $50 million in upfront payment in exchange for the rights. It will also receive undisclosed payments once certain milestones are met, as well as royalty on future sales.
CCX140 previously cleared phase 2 clinical trial in patients with diabetic kidney disease.
Vifor Pharma first partnered with ChemoCentryx in May for rights to a possible treatment for rare and orphan kidney diseases, CCX168, in certain parts of the world.